CPC Exosomes Reduce Apoptosis in Viral Myocarditis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current stem cell therapies for conditions like viral myocarditis have limitations, including invasive procedures and limited efficacy in reducing inflammation and improving myocardial function, while exosomes offer a cell-free method for therapeutic delivery.

Innovation Solution

Exosomes isolated from expanded rat cardiac progenitor cells (CPCs) are used to reduce CVB3-induced apoptosis and improve myocardial function by inhibiting viral replication through specific signaling pathways.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If stem cell therapies are used to treat viral myocarditis, then therapeutic effects are achieved, but invasive procedures and limited efficacy in reducing inflammation occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidinvasive procedures

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent extracts the therapeutic components (exosomes) from the stem cells themselves, isolating and purifying exosomes that contain anti-inflammatory and regenerative factors. This extraction allows the therapeutic effects to be delivered without requiring actual stem cell transplantation, thereby eliminating the need for invasive procedures while maintaining therapeutic efficacy.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses exosomes as intermediary carriers that mediate the therapeutic effects between stem cells and target tissues. These exosomes serve as a bridge, delivering bioactive molecules (miRNAs, proteins, lipids) to injured cardiac tissue without requiring direct stem cell injection, thus reducing invasiveness while preserving the ability to reduce inflammation and improve myocardial function.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of operation

If exosomes are used for therapeutic delivery, then cell-free method is achieved, but specific signaling pathways and mechanisms need to be identified

Engineering Contradiction:

Improvecell-free methodVSAvoidsignaling pathways

Core Design Contradiction:

Ease of operationVSDifficulty of detecting and measuring

Solution Approach 1:

The patent employs feedback mechanisms by analyzing the cargo composition of exosomes (miRNAs, proteins, lipids) and correlating this with their therapeutic effects. Through this feedback loop, the researchers identified specific signaling pathways (such as PI3K/Akt, MAPK/ERK) that are modulated by exosome delivery, thereby transforming the complexity of unknown mechanisms into identifiable and measurable pathways that can be targeted for therapeutic optimization.

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS20220296645A1Diagnostic and therapeutic uses of compositions comprising purified, enriched potent exosomes containing disease-based and therapy based signature cargo

Publication Date: 2022.09.22 SPIRITUS THERAPEUTICS INC

AI summary

The present disclosure provides a composition containing a purified and enriched population of potent exosomes derived from extracellular vesicles derived from mesenchymal stem cells (MSCs), a method for diagnosing a human subject aged over 50 years with an age-related chronic disease characterized by disease related dysfunction and optimally treating the subject, and a method for reprogramming a donated organ or tissue comprising a fibrotic disposition including treating the donated organ or tissue with a composition comprising purified enriched population of potent exosomes derived from extracellular vesicles derived from MSCs of a normal healthy subject.